Novel breakers of advanced glycation endproducts

A method of reversing deleterious effects of aging in an organism wherein said effects are formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

• 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
• 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid;
• L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
• 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
• methylene bis [4,4′-(2-chlorophenylureidophenoxyisobutyric acid)];
• 1,1-dimethylbiguanide;
• and
• 5-aminosalicylic acid.

A method of reversing complications resulting from diabetes wherein said complications result from formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

• 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
• 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid;
• L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
• 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
• methylene bis [4,4′-(2-chlorophenylureidophenoxyisobutyric acid)];
• 1,1-dimethylbiguanide;
• and
• 5-aminosalicylic acid.

A method of reversing progress in a patient of rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, or atherosclerosis, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

• 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
• 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid;
• L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
• 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
• methylene bis [4,4′-(2-chlorophenylureidophenoxyisobutyric acid)];
• 1,1-dimethylbiguanide;
• and
• 5-aminosalicylic acid.